Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies and the evolving understanding of complex malignancies. We open with an editorial by Mohammad Ammad […]

Jean-Luc Van Laethem, ASCO GI 2021: Results of the KEYNOTE-224 Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 23rd 2021

We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) about the efficacy and safety findings of the KEYNOTE-224 study (Clinical Trial Identifier: NCT02702414).

The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.

Questions

  1. What was previously known about the use of pembrolizumab in the treatment of patients with advanced hepatocellular carcinoma (HCC)? (0:37)
  2. Could you tell us a little about the aims and design of KEYNOTE-224? (2:54)
  3. What were the efficacy and safety findings of the study? (4:50)

Disclosures: Jean-Luc Van Laethem has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of ASCO GI 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup